Form 4: Organon R&D Head Exercises RSUs, Sells Shares for Tax

Organon & Co.'s Head of R&D and CMO, Juan Camilo Arjona Ferreira, reported the exercise of Restricted Stock Units and subsequent sale of shares for tax withholding purposes.

Summary

• Juan Camilo Arjona Ferreira, Head of R&D and CMO of Organon & Co. (OGN), reported transactions on March 29, 2026.
• Acquired 8,865 shares of common stock through the exercise of Restricted Stock Units (RSUs) at a price of $0.
• Disposed of 3,181 shares of common stock at a price of $5.84 per share to cover tax liabilities related to the RSU vesting.
• The price of $5.84 per share was the closing market price of Organon common stock on Friday, March 27, 2026, as required by the RSU plan.
• Following these transactions, Arjona Ferreira beneficially owns 21,436.477 shares of Organon common stock.
• The reported beneficial ownership includes an addition of 708.122 shares from dividend equivalents, net of withholding tax, not previously required to be reported.
• The total number of shares beneficially owned was previously reduced by 13,872 shares transferred under Exchange Act Rule 16a-12.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents the executive realizing compensation and maintaining a significant stake, which is a normal and expected part of executive compensation, indicating continued alignment with shareholder interests.

Positives

• The executive realized compensation through the vesting and exercise of 8,865 Restricted Stock Units.
• The net effect of the transactions is an increase in direct beneficial ownership of Organon common stock after accounting for tax withholding.

Negatives

• A portion of the acquired shares (3,181 shares) was immediately sold to cover tax obligations, reducing the net increase in direct ownership.

Future Outlook

The filing indicates future vesting dates for the remaining Restricted Stock Units on March 29, 2025, and March 29, 2027, suggesting continued executive compensation realization over time.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the exercise of Restricted Stock Units and subsequent sale for tax withholding, are common in the pharmaceutical and biotechnology industries as part of executive compensation packages. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather the scheduled realization of equity awards.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not indicate a change in company fundamentals. It shows an executive realizing value from their equity awards.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Remaining Restricted Stock Units are scheduled to vest and be distributed on March 29, 2025, and March 29, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of Restricted Stock Units and a subsequent sale of shares for tax purposes. Such transactions are standard for executive compensation and do not typically signal a change in the company's fundamental outlook or performance. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new information warranting a change in investment thesis.

Keywords

Organon, OGN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Share Acquisition, Tax Withholding, Juan Camilo Arjona Ferreira